🇺🇸 FDA
Pipeline program

Enzalutamide 40mg

CCR5461

Phase 2 small_molecule active

Quick answer

Enzalutamide 40mg for Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials